<DOC>
	<DOCNO>NCT02925559</DOCNO>
	<brief_summary>Objectives Primary objective : To access change baseline week 12 MAGE index glycemic variability measure CGMS dapagliflozin versus . gliclazide MR . Secondary objective : 1 . Change baseline week 12 glycated hemoglobin A1c ( HbA1c ) , fast plasma glucose , postprandial glucose achievement HbA1c ≤6.5 % &lt; 7 % end study ) dapagliflozin versus gliclazide MR. 2 . Change baseline week 12 glycemic variability define interquartile range ( IQR - interval 25th 75th percentile ) measure CGMS dapagliflozin versus gliclazide MR. 3 . Change baseline week 12 glycemic variability measure Standard Deviation mean glycemia ( SD ) measure CGMS dapagliflozin versus gliclazide MR. 4 . Change baseline week 12 glycemic variability measure Coefficient Variation ( CV ) measure CGMS dapagliflozin versus gliclazide MR. 5 . Change baseline week 12 time spend hypoglycemic range ( glycemia &lt; 70mg/dL ) measure CGMS dapagliflozin versus gliclazide MR. Study design This single-center , prospective , randomize , open-label , comparative , phase IV study compare effect gliclazide MR dapagliflozin Glycemic Variability patient Type 2 Diabetes Mellitus ( T2DM ) . All patient treatment naïve receive standard care therapy T2DM well co-morbidities base accepted guideline local best practice . Target patient population Approximately 120 patient T2DM randomize study site . Patients treat metformin inadequate glycemic control time enrollment well treatment naïve non-medically treat ( e.g. , diet ) patient , enrol receive either dapagliflozin 10mg qd comparator gliclazide MR 120mg qd addition standard care treatment T2DM co-morbidities . Investigational product , dosage mode administration Dapagliflozin 10mg tablet administer orally daily 12 week . Comparator , dosage mode administration Gliclazide MR 60mg tablet administer orally , 2 tablet daily 12 week . Duration treatment The treatment study medication comparator total duration 15 week .</brief_summary>
	<brief_title>Effect Anti-diabetic Drugs Glycemic Variability</brief_title>
	<detailed_description>INTRODUCTION Dapagliflozin highly potent , selective , reversible inhibitor sodium-glucose cotransporter-2 ( SGLT2 ) , major transporter responsible renal glucose reabsorption.1 Dapagliflozin lower plasma glucose inhibit renal reabsorption glucose promote urinary excretion patient type 2 diabetes mellitus ( T2DM ) . Gliclazide MR highly potent selective sulphonylurea consider specialist reference class , low risk hypoglycemia increase cardiovascular mortality . Gliclazide MR increase physiological mechanism insulin secretion , thus reduce postprandial fast glucose level patient type 2 diabetes . There increase large amount evidence show rapid fluctuation blood glucose high glycemic variability may important role development diabetes complication . Cardiovascular disease , endothelial dysfunction oxidative stress common complication among patient type 2 diabetes glycemic variability may important factor development . Previous study show vildagliptin , dipeptidyl peptidase 4 inhibitor ( DPP-4 inhibitor ) , could improve mean blood glucose also 24-hour glucose fluctuation restore physiological pattern insulin glucagon secretion . SGLT-2 inhibitor novel anti-diabetic drug currently publish study evaluate effect glycemic variability calculate widely use method like mean amplitude glycemic excursion ( MAGE ) , standard deviation mean glycemia ( SD ) , coefficient variation ( CV ) interquartile range ( IQR ) . The aim current study compare effect gliclazide MR dapagliflozin glycemic variability use continuous glucose monitoring system ( CGMS ) determine MAGE , SD , CV IQR . 2 . METHODOLOGY 2.1 Study Population ( Target population Clinical Trial Subjects ) A total 120 patient document Type 2 Diabetes enrol , consider expect screening failure rate 30 % ( n=22 ) expect dropout rate 8 % ( n=10 ) , base previous study conduct center use similar population period . We estimate 88 ( 44 group ) subject complete protocol procedure . Per-protocol analysis restrict participant fulfill protocol term eligibility , intervention outcome assessment . To close real life scenario possible , clinical trial include subject patient treat metformin inadequate glycemic control time enrollment well treatment naïve non-medically treat ( e.g. , diet ) patient . 2.2 Investigational Product , Posology Method Administration The active treatment include 10 mg dose dapagliflozin orally day . 2.3 Comparator , Posology Method Administration As comparator , gliclazide MR administer dose 120 mg orally day . 2.4 Study Duration The study expect total duration 15 month ( 12 month recruitment 12 week active treatment ) . 2.5 Methods Assessments Patients randomized revision inclusion exclusion criterion . Randomization occur 1:1 manner use validate computerized system completion 88 randomized patient . Patients group 1 ( n~44 ) receive study medication ( dapagliflozin ) one Group 2 ( n~44 ) receive comparator gliclazide MR top usual treatment type 2 diabetes . Treatments study medication comparator last 12+/-1 week . All patient group receive guideline diet ( caloric macronutrient content ) physical activity dietitian study site begin study . A `` blinded patient '' Continuous Glucose Monitoring System ( CGMS , iPro2 ( TM ) Enlite-Sensor ( TM ) ; Medtronic Mini-Med Inc. , Northridge , California , USA ) insert subcutaneously . The sensor glucose oxidase-based platinum electrode insert needle subcutaneous tissue anterior abdominal wall allow 288 glucose reading per day . The CGMS place 72 hour begin ( last three day run-in phase ) start study medication end study last three day study treatment . The validated software Glyculator ( TM ) EasyGV ( TM ) calculate glycemic variability parameter MAGE , SD CV IQR calculate software Captür-AGP ( TM ) . Biochemical marker glycemic control ( HbA1c , fast glucose postprandial glucose ) determine begin end treatment period . Each patient maintain regular visit assistant doctor . At end , two group compare accord follow parameter calculate base result obtain CGMS test , blood sample patient Clinical Research Form ( CRF ) - Glycemic variability parameter : MAGE , SD , CV IQR - Glycemic control parameter : HbA1c , fast glucose postprandial glucose - Exploratory variable : incidence urinary tract Infection genital infection incidence volume depletion . 2.6 Sample size Statistical method To determine sample size obtain clinical statistical significant result primary variable ( difference &gt; 14.5mg/dL glycemic variability ) , use MAGE ( mean amplitude glycemic excursion ) . As MAGE glycemic amplitude measure mg/dL , arbitrarily set difference ≥ 14.5 , may clinically important patient judge study center team expert consultant . There good study T2DM patient establish MAGE difference improvement could significant prevent diabetes complication . Sample size calculate base provided parameter : significance level ( adjusted sidedness ) = 0.025 , standard deviation MAGE = 24mg/dL , power = 0.8 , between-group difference mean MAGE equal 14.5 mg/dL . The variable calculated total number patient . A total 44 patient group ( dapagliflozin 10 mg gliclazide MR 120 mg ) must complete two-treatment parallel-design study . Considering expect screening failure rate 30 % ( n=11 per group ) expect dropout rate 8 % ( n=5 per group ) , base previous study center use similar population period , total 60 patient per group ( 120 total ) enrol . Demographic baseline characteristic represent distribution frequency summarize statistic base dataset , treatment group clinical trial subject combine . The main baseline characteristic present . ANCOVA use adjustment baseline value . For primary secondary variable , quantitative , use Student 's t-test Mann-Whitney test statistical evaluation comparison group . In test , use significance level 5 % p &lt; 0.05 . 2.7 Study Design Rationale This single-center , Prospective , Randomized , Open-label , Comparative , Phase IV Study compare effect gliclazide MR dapagliflozin Glycemic Variability patient Type 2 Diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>A . Informed consent form obtain studyrelated activity . Studyrelated activity procedure would perform normal treatment patient . B . All study subject must patient diagnose type 2 diabetes base current guideline Brazilian Society Diabetes and/or American Diabetes Association ( ADA ) follow criterion : Age ≥40 year old . HbA1c ≥7 % randomization . Drug naïve metformin treat stable dose least 3 month . 1 . Acute vascular event ( cardiac , cerebral peripheral ) least 2 month randomization . 2 . Patient chronic dialysis and/or renal transplantation and/or serum creatinine &gt; 1.5 mg/dL and/or estimate glomerular filtration rate ( eGFR ) &lt; 45ml/min ( MDRD ) and/or Creatinine Clearance &lt; 60ml/min . 3 . Patients HIV , severe autoimmune disease chronic treatment oral steroid ( &gt; 30 consecutive day ) . 4 . Current previous treatment SGLT2 inhibitor within 2 month prior randomization . 5 . Current previous treatment type insulin within 2 month prior randomization . 6 . Current previous treatment sulphonylurea meglitinide within 2 month prior randomization . 7 . Current previous treatment DPP4 inhibitor glucagonlike peptide1 ( GLP1 ) receptor agonist within 2 month prior randomization . 8 . Current previous treatment acarbose within 2 month prior randomization . 9 . Sustained arterial hypertension ≥160/100mm Hg . 10 . Body mass index ( BMI ) &gt; 50 kg/m² . 11 . HbA1c ≥10.5 % randomization . 12 . Transaminases ( aspartate aminotransferase and/or alanine aminotransferase ) &gt; 2.5 x upper limit normal . 13 . Total bilirubin &gt; 2.5 x upper limit normal 14 . Chronic liver disease alcoholic liver disease . 15 . LDLcholesterol &gt; 250 mg/dL ( &gt; 6.48 mmol/L ) . 16 . Triglycerides &gt; 1000 mg/dL ( &gt; 11.3 mmol/L ) . 17 . HDLcholesterol &lt; 25 mg/dL ( &lt; 0.64 mmol/L ) . 18 . Positive haematuria observe urine sample obtain runin visit . 19 . Prescription investigational medication within 3 month screen visit . 20 . Prescription investigational medication within period 3 month one year screen visit ( visit 1 ) , unless direct benefit study subject , discretion investigator . 21 . Pregnant breastfeeding patient . 22 . Previous participation study . 23 . Individuals risk poor adherence protocol medication . 24 . Any condition make patient unable complete study within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glycemic Variability</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Gliclazide MR</keyword>
	<keyword>Continuous Glucose Monitoring</keyword>
	<keyword>Mean Amplitude Glycemic Excursions</keyword>
	<keyword>MAGE</keyword>
</DOC>